ArticleCardiology research2026
Renal Denervation: A Multicenter, Real-World Experience.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal denervation (RDN) has emerged as a promising device-based therapy for the management of resistant hypertension (RH). However, real-world evidence of effectiveness and safety in the Indian population remains limited. This study aimed to evaluate the efficacy and safety of catheter-based RDN in reducing blood pressure (BP) and antihypertensive medication burden among Indian patients with RH. Methods: This retrospective, multicenter, real-world study included 26 consecutive patients who underwent RDN across 21 tertiary care centers in India. Patients were followed at discharge and at 1, 3, 6, and 12 months after the procedure. The primary endpoint was the change in office BP at 12 months. Secondary endpoints included changes in antihypertensive medication burden and procedure-related safety outcomes. Results: The mean age of the study population was 60.7 ± 13.8 years, and 61.5% were male. Baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 186.2 ± 18.8 and 98.7 ± 25.3 mm Hg, respectively. Significant reductions in BP were observed at all follow-up time points. At 12 months, mean SBP and DBP decreased to 121.7 ± 10.5 and 75.9 ± 4.7 mm Hg, corresponding to reductions of 63.4 and 24.7 mm Hg, respectively (both P < 0.001). The mean number of antihypertensive medication classes was significantly reduced from 5.12 ± 1.70 at baseline to 2.00 ± 0.80 at 1 year (P < 0.001). No major periprocedural complications or adverse events were reported. One patient experienced an access-site vascular complication involving the superficial femoral artery, which was successfully managed with covered stent implantation without further sequelae. Conclusions: RDN was associated with significant and sustained reductions in BP and antihypertensive medication burden over 12 months. The procedure demonstrated a favorable safety profile, supporting its role as an as a safe and effective adjunctive treatment option for patients with RH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.